Design, synthesis and biological activity of a targeted library of potential tryptase inhibitors

Organic and Biomolecular Chemistry

Volumn 2, Issue 11, 2004, Pages 1633-1642

  García, Monica ^a,b   Del Río, Xavier ^a,b   Silvestre, Sandra ^b   Rubiralta, Mario ^a,b   Lozoya, Estrella ^c   Segarra, Victor ^c   Fernández, Dolors ^c   Miralpeix, Montserrat ^c   Aparici, Mònica ^c   Diez, Anna ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c Almirall Prodesfarma ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBONS; CONFORMATIONS; DIMERIZATION; HYDROGENATION; KETONES; RESINS; SYNTHESIS (CHEMICAL);

ACTIVATING AGENTS; TRYPTASE INHIBITORS;

ENZYME INHIBITION;

3 AMINOPIPERIDINE 2 ONE; 3-AMINOPIPERIDINE-2-ONE; PIPERIDONE DERIVATIVE; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRYPTASE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; DRUG DESIGN; HUMAN; SYNTHESIS;

DIMERIZATION; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PIPERIDONES; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; TRYPTASES;

EID: 2942735354     PISSN: 14770520     EISSN: None     Source Type: Journal    
DOI: 10.1039/b403629h     Document Type: Article

References (39)

1. C. P. Sommerhoff, W. Bode, G. Matschiner, A. Bergner and H. Fritz, Biochim. Biophys. Acta. 2000, 1477, 75-89.
2. C. P. Sommerhoff, C. Söllner, R. Mentele, G. P. Piechottka, E. A. Auerswald and H. Fritz, Biol. Chem., 1994, 375, 685-694.
3. Number of reviews on tryptase inhibitors in the last 3 years: 22. Number of patents in the last 3 years: 51.
4. G. H. Caughey, W. W. Raymond, E. Bacci, R. J. Lombardy and R. R. Tidwell, J. Pharmacol. Exp. Theor., 1993, 264, 676-682.
5. D. S. Jackson, S. A. Fraser, L-M. Ni, C-M. Kam, U. Winkler, D. A. Johnson, C. J. Froelich, D. Hudig and J. C. Powers, J. Med. Chem., 1998, 41, 2289-2301.
6. K. D. Combrink, H. B. Gülgeze, N. A. Meanwell, B. C. Pearce, P. Zulan, G. S. Bisacchi, D. G. M. Roberts, P. Stanley and S. M. Seiler, J. Med. Chem., 1998, 41, 4854-4860.
7. J. M. Clark, W. R. Moore and R. D Tanaka, Drugs Future, 1996, 21, 811-816.
8. (a) J. M. Dener, E. Y. Kuo, K. D. Rice, V. R. Wang, W. B. Young, WO 1998-04537-A1, Int. Appl. US1997/13422;
9. (b) J. M. Dener, K. D. Rice, A. R. Gangloff, E. Kuo, WO 1996-09297-A1, Int. Appl. US1995/11814;
10. (c) P. J. Belshawl, D. M. Spencer, G. R. Crabtree and S. L. Schreiber, Chem. Biol., 1996, 3, 731-738.
11. K. D. Rice, V. R. Wang, A. R. Gangloff, E. Y. Kuo, J. M. Dener, W. S. Nexcomb, W. B. Young, D. Putman, L. Cregar, M. Wong and P. J. Simpson, Bioorg. Med. Chem. Lett., 2000, 10, 2361-2366.
12. (a) For other applications of 3-amino-2-piperidones as pseudo-peptides, see: M. A. Estiarte, M. Rubiralta, A. Diez, M. Thormann and E. Giralt, J. Org. Chem., 2000, 65, 6992-6999:
13. (b) J. Piró, P. Forns, J. Blanchet, M. Bonin, L. Micouin and A. Diez, Tetrahedron: Asymmetry, 2002, 13, 995-1004;
14. (c) C. Escolano, M. Rubiralta and A. Diez, Tetrahedron Lett., 2002, 43, 4343-4346;
15. (d) M. M. Fernández, A. Diez, M. Rubiralta, E. Montenegro, N. Casamitjana, M. J. Kogan and E. Giralt, J. Org. Chem., 2002, 67, 7587-7599;
16. (e) M. Ecija, A. Diez, M. Rubiralta, N. Casamitjana, M. J. Kogan and E. Giralt, J. Org. Chem., 2003, 68, 9541-9553.
17. J. E. Semple, D. C. Rowley, T. K. Brunck, T. Ha-Uong, N. K. Minami, T. D. Owens, S. Y. Tamura, E. A. Goldman, D. V. Siev, R. J. Ardecky, S. H. Carpenter, Y. Ge, B. M. Richard, T. G. Nolan, K. Håkanson, A. Tulinsky, R. F. Nutt and W. C. Ripka, J. Med. Chem., 1996, 39, 4531-4536.
18. For a review on the syntheses of 3-aminopiperidones in solution, see: (a) C. Flamant-Robin, Q. Wang and N. A. Sasaki, Tetrahedron Lett., 2001, 42, 8483-8484; (b) J. Aubé, Advances in Amino Acid Mimetics and Peptidomimetics, JAY Press Inc, 1997, vol. 1, p. 193.
19. For a review on the syntheses of 3-aminopiperidones in solution, see: (a) C. Flamant-Robin, Q. Wang and N. A. Sasaki, Tetrahedron Lett., 2001, 42, 8483-8484; (b) J. Aubé, Advances in Amino Acid Mimetics and Peptidomimetics, JAY Press Inc, 1997, vol. 1, p. 193.
20. The only precedent of a lactamisation on solid phase was reported as a side-reaction in the context of an intramolecular amino acid coupling: Y. Lee and R. B. Silverman, Synthesis, 1999, 495-1499.
21. M. García, A. Serra, M. Rubiralta, A. Diez, V. Segarra, E. Lozoya, H. Ryder and J. M. Palacios, Tetrahedron: Asymmetry, 2000, 11, 991-994.
22. The resin was functionalised as an active carbonate according to: J. Alsina, C. Chiva, M. Ortiz, F. Rabanal, E. Giralt and F. Albericio, Tetrahedron Lett., 1997, 38, 883-886.
23. J:A. Jcsey, C. A. Tarlton and C. E. Payne, Tetrahedron Lett., 1998, 39, 5899-5902.
24. J. A. Gavin, M. E. García, A. J. Benesi and T. E. Mallouk, J. Org. Chem., 1998, 63, 7663-7669.
25. For the procedure and preliminary results see: M. Garcia, M. Rubiralta, A. Diez, H. Ryder, E. Lozoya and V. Segarra, in Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries: Peptides, Proteins and Nucleic Acids-Small Molecule Organic Chemical Diversity, Collected Papers, International Symposium, 7th. Southampton, United Kingdom, Sept. 18-22, 2002, Ed. R. Epton, Mayflower Worldwide Ltd, Kingswinford, UK, p. 205.
26. Alloc-cyclo-Orn was synthesized in solution by cyclodehydration of L-ornithine according to: A. Bladé-Font, Tetrahedron Lett., 1980, 21, 2443-2446 and subsequent protection of the α-amino with an allyloxycarbonyl group following the protocol by E. J. Corey and J. W. Suggs, J. Org. Chem., 1973, 38, 3223-3224. The sample was not optically pure.
27. Alloc-cyclo-Orn was synthesized in solution by cyclodehydration of L-ornithine according to: A. Bladé-Font, Tetrahedron Lett., 1980, 21, 2443-2446 and subsequent protection of the α-amino with an allyloxycarbonyl group following the protocol by E. J. Corey and J. W. Suggs, J. Org. Chem., 1973, 38, 3223-3224. The sample was not optically pure.
28. Compound 28 was characterised by the NMR and HPLC data of the product cleaved from an aliquot of the resin. The purity determined by HPLC was higher than 95%.
29. (a) C. G. Boojamra, K. M. Burow, L. A. Thompson and J. A. Ellman, J. Org. Chem., 1997, 62, 1240-1256;
30. (b) F. X. Woolard, J. Paetsch and J. A. Ellman, J. Org. Chem., 1997, 62, 6102-6103.
31. S. E. Schneider, P. A. Bishop, M. A. Salazar, O. A. Bishop and E. V. Anslyn, Tetrahedron, 1998, 54, 15063-15086.
32. J. I. Crowley and H. Rapoport, Acc. Chem. Res., 1976, 9, 135-144.
33. (a) P. Castan, E. Giralt, J. C. Pérez, J. M. Ribó, N. Siscart and F. Trull, Tetrahedron. 1987, 43, 2593-2608:
34. th European Peptide Symposium, Montpellier, 2000.
35. th European Peptide Symposium, Montpellier, 2000.
36. M. del Fresno, J. Alsina, M. Royo, G. Barany and F. Albericic, Tetrahedron Lett., 1998, 39, 2639-2642.
37. -1.
38. The manipulation of the resulting dimer was delicate, mainly because of its size and polarity.
39. We expected to obtain three stereoisomers for compounds 7 prepared from racemic lactams: the racemic RR and SS forms and the meso epimer RS. However, we could not detect the diastereomeric mixture by standard methods such as NMR and analytical HPLC. Since the compounds turned out not to be sufficiently active, we did not pursue this issue.